RE: Covid puts aids victims at even more risk27 Oct 2021 20:02
@Blubutton
From the AGM :
In terms of our Global Health Division, we remain optimistic about the long-term prospects for the roll-out of our VISITECT® CD4 Advanced Disease test, the first and the world's only instrument-free point of care test for monitoring CD4 levels, essential for the effective management of advanced HIV. We have received excellent feedback from external clinical studies and evaluations in key countries and can see positive indications that long term funders are supporting the roll out of the Advanced Disease initiative. We therefore remain confident that the market potential for our product reaching 4m to 6m tests a year within the next three to five years, representing an opportunity to generate £12m to £18m in annualised revenues.
( £12m to £18m per year )
Yes I agree in the meantime it would be nice
to see the Home use RNS and sales order RNS
coming in quick succession for those that are un invested…..Trick or treat : )